Cyclic GMP and phosphodiesterase 5 inhibitor therapies: What's on the horizon

Molecular Pharmacology

Volumn 66, Issue 1, 2004, Pages 11-13

  Lincoln, Thomas M ^a  

^a UNIVERSITY OF SOUTH ALABAMA COLLEGE OF MEDICINE   (United States)

Author keywords

[No Author keywords available]

Indexed keywords

CYCLIC GMP; ILOPROST; NESIRITIDE; NITRATE; NITRIC OXIDE; PHOSPHODIESTERASE V INHIBITOR; SILDENAFIL; TADALAFIL; VARDENAFIL;

ANIMAL MODEL; BINDING AFFINITY; CLINICAL TRIAL; CONGESTIVE HEART FAILURE; DISSOCIATION; DRUG ACTIVITY; DRUG CONTRAINDICATION; DRUG EFFECT; DRUG EFFICACY; DRUG INDICATION; DRUG MECHANISM; DRUG POTENCY; DRUG PROTEIN BINDING; DRUG TARGETING; ENZYME ACTIVITY; ENZYME INHIBITION; ERECTILE DYSFUNCTION; HEART DISEASE; HUMAN; NONHUMAN; PRIORITY JOURNAL; PROTEIN HYDROLYSIS; PROTEIN METABOLISM; PROTEIN SYNTHESIS; PULMONARY HYPERTENSION; RETINA ISCHEMIA; REVIEW; SIDE EFFECT; VISUAL IMPAIRMENT;

3',5'-CYCLIC-GMP PHOSPHODIESTERASE; ANIMALS; CYCLIC GMP; CYCLIC GMP-DEPENDENT PROTEIN KINASES; HUMANS; IMPOTENCE; MALE; PHOSPHODIESTERASE INHIBITORS;

EID: 3042672838     PISSN: 0026895X     EISSN: None     Source Type: Journal    
DOI: 10.1124/mol.104.001388     Document Type: Review

References (11)

1. Blount MA, Beasley A, Zoraghi R, Sekhar KR, Bessay EP, Francis SH, and Corbin JD (2004) Binding of tritiated sildenafil, tadalafil, vardenafil to the phosphodiesterase-5 catalytic site displays potency, specificity, heterogeneity, and cGMP stimulation. Mol Pharmacol 66:144-152.
2. Boolell M, Allen MJ, Ballard SA, Gepi-Attee S, Muirhead GJ, Naylor AM, Osterloh IH, and Gingell C (1996) Sildenafil: an orally active type 5 cyclic GMP-specific phosphodiesterase inhibitor for the treatment of penile erectile dysfunction. Int J Impot Res 8:47-52.
3. Brindis RG and Kloner RA (2003) Sildenafil in patients with cardiovascular disease. Am J Cardiol 92:26-36.
4. Gresser U and Gleiter CH (2002) Erectile dysfunction: comparison of efficacy and side effects of the PDE-5 inhibitors sildenafil, vardenafil and tadalafil: review of the literature. Eur J Med Res 7:435-446.
5. Humbert M and Simonneau G (2004) Sildenafil for pulmonary arterial hypertension: still waiting for evidence. Am J Respir Crit Care Med 169:6-7.
6. Ignarro LJ, Bush GM, Buga KS, Wood KS, Fukuto JM, and Rajfer J (1990) NO and cyclic GMP formation upon electrical field stimulation causes relaxation of corpus cavernosum smooth muscle. Biochem Biophys Res Commun 170:843-850.
7. Lee JI, Park H, Kim JH, Lee SI, and Conklin JL (2003) The effect of sildenafil on oesophageal motor function in healthy subjects and patients with nutcracker oesophagus. Neurogastrointest Motil 15:617-623.
8. Polak K, Wimpissinger B, Berisha F, Georgopoulos M, and Schmetterer L (2003) Effects of sildenafil on retinal blood flow and flicker-induced retinal vasodilatation in healthy subjects. Investig Ophthalmol Vis Sci 44:4872-4876.
9. Refflemann T and Kloner R (2003) Therapeutic potential of phosphodiesterase 5 inhibition for cardiovascular disease. Circulation 108:239-247.
10. Rosenkranz S, Diet F, Karasch T, Weibrauch J, Wassermann K, and Erdmann E (2003) Sildenafil improved pulmonary hypertension and peripheral blood flow in a patient with scleroderma-associated lung fibrosis and the Raynaud phenomenon. Ann Intern Med 139:871-873.
11. Zinch I, Schofield RS, and Johnson JA (2003) The evolving role of nesiritide in advanced or decompensated heart failure. Pharmacotherapy 23:1266-1280.